Mumbai, March 10 -- Pharma Major Sun Pharma has entered into an agreement for the acquisition of all the outstanding shares of Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology company.
Checkpoint, a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers.
Dilip Shanghvi, chairman & managing director of Sun Pharma, said: "Combining UNLOXCYT, an FDA approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma's global presence means patients with cSCC may soon have access to an important, new treatment option. The acquisition further bolsters our innovative portfolio in onco-derm therapy."
Checkpoint has received approval from...